Table 2 Combinational therapies with SE inhibitors in clinical trials
From: Oncogenic seRNA functional activation: a novel mechanism of tumorigenesis
Drug name | Target | Combination | Disease | Status | Phase | NCT number |
|---|---|---|---|---|---|---|
FT-1101 | BET | Azacitidine | AML, MDS or non-hodgkin lymphoma (NHL) | Completed | 1 | 02543879 |
CPI-0610 | BET | Ruxolitinib | Myelofibrosis | Recruiting | 2 | 02158858 |
BMS-986158 | BET | Nivolumab | Advanced tumors | Recruiting | 2 | T02419417 |
RO6870810 | BET | Daratumumab | Relapsed/refractory multiple myeloma | Active, not Recruiting | 1 | 03068351 |
SY-1365 | CDK7 | Carboplatin or Fulvestrant | Advanced solid tumors, ovarian cancer, breast cancer | Recruiting | 1 | 03134638 |
CT7001 | CDK7 | Fulvestrant | Advanced solid malignancies | Recruiting | 2 | 03363893 |
BCD-115 | CDK8/19 | Endocrine therapy | Breast cancer | Completed | 1 | 03065010 |
PD-0332991/ Palbociclib | CDK4/6 | Binimetinib | Lung cancer | Recruiting | 1 | 03170206 |
LEE011/Ribociclib | CDK4/6 | Ceritinib | Non-small cell lung cancer | Completed | 1 | 02292550 |
PD-0332991/ Palbociclib | CDK4/6 | Nab-Paclitaxel | Metastatic pancreatic ductal adenocarcinoma | Completed | 1 | 02501902 |
Trilaciclib /G1T28 | CDK4/6 | Etoposide and Carboplatin | Small cell lung cancer | Completed | 1b/2a | 02499770 |